Xolremdi
Xolremdi ingredients
| Active ingredient | Strength |
|---|---|
| Mavorixafor | 100 mg/1 |
What Xolremdi is used for
The FDA lists the approved uses on the official label (below). In the EU, mavorixafor is approved as Xolremdi for:
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Xolremdi
- Generic name
- Mavorixafor
- Made by
- X4 Pharmaceuticals, Inc.
- Forms
- Capsule, Gelatin Coated
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA218709
- On the US market since
- 2024
Official information
- Xolremdi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Mavorixafor)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xolremdi?
Xolremdi (Mavorixafor) is a specialist medicine made by X4 Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Xolremdi?
Xolremdi contains Mavorixafor (100 mg/1).
Is Xolremdi approved in Europe?
The same active substance is approved in the EU as Xolremdi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA